Amgen Faces Antitrust Lawsuit Over Alleged Anticompetitive Practices in Enbrel Pricing

Amgen Inc., the manufacturer of the widely-used arthritis drug Enbrel, is facing serious allegations of anticompetitive conduct. According to a recent antitrust class action lawsuit, a 50-mg dose of Enbrel now costs patients a staggering $7,401.83 per month, which represents a 643% increase since the drug was launched in 1998. These allegations highlight concerns over the pricing strategies employed by big pharmaceutical companies and their impact on consumers.